Evidence map›Paper›PMID 42602005›Full record

ArticleFrontiers in oncology2026

Case Report: Synchronous germline

Huilei Yu, Dandan Wang, Ying Han, Yiyi Li, Juntao Zhang

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Huilei YuDepartment of Ophthalmology, Ningbo University Affiliated People's Hospital, Ningbo, China.
Dandan WangDepartment of Ophthalmology, Ningbo University Affiliated People's Hospital, Ningbo, China.
Ying HanDepartment of Ophthalmology, Ningbo University Affiliated People's Hospital, Ningbo, China.
Yiyi LiDepartment of Ophthalmology, Ningbo University Affiliated People's Hospital, Ningbo, China.
Juntao ZhangDepartment of Ophthalmology, Ningbo University Affiliated People's Hospital, Ningbo, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Synchronous occurrence of choroidal melanoma and clear cell renal cell carcinoma (ccRCC) is exceptionally rare and traditionally suspicious for Case presentation: A 64-year-old Chinese male with a 2-year history of progressive vision loss in his right eye was found to have an intraocular melanocytic tumor by multimodal imaging. Staging PET/CT incidentally detected a hypermetabolic mass in the right kidney. Guided by imaging and multidisciplinary team (MDT) discussion, the patient underwent right eye enucleation followed by right partial nephrectomy. Histopathology and immunohistochemistry supported two independent localized primary tumors: mixed-cell choroidal melanoma (AJCC 8th edition stage II, pT2aN0M0) and ccRCC (pT1bN0M0, WHO/ISUP grade 2). Postoperative comprehensive genomic profiling provided supportive molecular evidence, showing a Conclusion: This case illustrates that multimodal imaging and multidisciplinary assessment can guide curative-intent management for synchronous early-stage tumors, while postoperative genomic profiling can add supportive molecular evidence and inform genetic counseling. Low-VAF renal genomic findings should be interpreted cautiously and in the context of histology and immunophenotype. Long-term surveillance remains essential.

Indexed as

BAP1 tumor predisposition syndromecase reportchoroidal melanomaclear cell renal cell carcinomadouble primary tumors

Identifiers

PMID42602005
PMCPMC13472860

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.